Pharma Nobis LLC Initiates Class II Recall of Magnesium Citrate Oral Solution Due to Microbial Contamination
Pharma Nobis LLC has initiated a Class II recall for 53,268 bottles of Freskaro Magnesium Citrate Oral Solution due to Acetobacter nitrogenifigens contamination. This voluntary action, originating from its Texarkana, TX facility, underscores critical quality control vulnerabilities in non-sterile drug manufacturing. Procurement and regulatory teams must reassess supplier qualification and internal cGMP adherence to mitigate supply chain disruption and ensure patient safety.
FDA Class II Recall: Pharma Nobis's Contaminated Magnesium Citrate Oral Solution
Pharma Nobis LLC has initiated a Class II voluntary recall, D-0230-2024, for its Freskaro refresh & revitalize Magnesium Citrate Saline Laxative Oral Solution, Grape Flavor. This significant regulatory action, initiated on December 21, 2023, targets 53,268 bottles of Lot A80553, with an expiration date of November 2025. The core issue driving this recall is microbial contamination, specifically the presence of *Acetobacter nitrogenifigens* bacteria within the non-sterile oral solution. For procurement directors and supply chain VPs, this event signals an immediate disruption in the availability of this specific Magnesium Citrate product from Pharma Nobis. The Class II classification by the FDA indicates that the contaminated product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. Business development executives must understand that such contamination events can erode market trust and necessitate swift, transparent communication to maintain customer confidence and market share for similar products. Regulatory affairs heads must immediately assess the implications for their own product portfolios, particularly those involving non-sterile liquid formulations, to ensure comparable risks are proactively managed.
Operational Impact of Microbial Contamination on Pharma Nobis's Texarkana Facility
The recall directly implicates manufacturing quality controls at Pharma Nobis LLC's facility located at 7400 Alumax Rd, Texarkana, TX 75501-0282, United States. The presence of *Acetobacter nitrogenifigens* in the Freskaro Magnesium Citrate Oral Solution (NDC 82645-311-10) points to a breakdown in aseptic or hygienic manufacturing practices for non-sterile products. For procurement directors, this means a critical re-evaluation of Pharma Nobis as a supplier, requiring detailed insight into their root cause analysis and corrective and preventive actions (CAPAs). Supply chain VPs face the challenge of securing alternative sources for Magnesium Citrate, a widely used over-the-counter laxative, to prevent stockouts and maintain market supply. The recall of 53,268 bottles represents a substantial volume that needs to be accounted for, impacting inventory management and distribution networks nationwide. Regulatory affairs heads must ensure that their internal quality systems are robust enough to prevent similar microbial ingress, particularly for oral solutions, which are susceptible to environmental contaminants if cGMP standards are not rigorously upheld.
Supply Chain Vulnerabilities for Magnesium Citrate Products
This Class II recall of Pharma Nobis's Magnesium Citrate Oral Solution highlights inherent vulnerabilities within the pharmaceutical supply chain for common OTC products. The nationwide distribution pattern of the affected lot (A80553) means that distributors, pharmacies, and ultimately consumers across the United States are impacted. For procurement directors, this event underscores the imperative of supplier diversification and robust qualification processes. Relying on a single source for key active pharmaceutical ingredients (APIs) or finished dosage forms, even for seemingly low-risk products like Magnesium Citrate, exposes businesses to significant disruption when quality issues arise. Supply chain VPs should review their risk mitigation strategies, including geographic diversification of suppliers and maintaining safety stock, to buffer against unforeseen recalls. Business development executives must consider how such events can shift market dynamics, creating opportunities for competitors with demonstrably strong quality systems. The incident serves as a stark reminder that even non-sterile products require stringent environmental controls and quality assurance to prevent contamination and maintain product integrity, safeguarding both patient health and commercial viability.
Navigating Heightened Regulatory Scrutiny: Implications for Pharmaceutical Manufacturers
The FDA's classification of this Pharma Nobis recall as Class II signals continued stringent oversight on pharmaceutical manufacturing quality across the industry. While the immediate action is a firm-initiated voluntary recall, the FDA's involvement in classification and monitoring of its 'ongoing' status indicates a broader regulatory focus on preventing contaminants like *Acetobacter nitrogenifigens*. This aligns with a pattern of increased scrutiny, as evidenced by recent Class I and Class II recalls involving major players such as Pfizer (for Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter) and Sandoz (for Enoxaparin Sodium due to temperature excursion risks). For regulatory affairs heads, this means a proactive approach to cGMP compliance is non-negotiable, extending beyond sterile products to all formulations. Procurement directors must integrate regulatory compliance history into their supplier selection criteria, understanding that a supplier's quality issues can cascade into significant business interruptions. Business development executives should leverage strong internal quality systems as a competitive differentiator, demonstrating unwavering commitment to product safety and regulatory adherence in a market under constant FDA vigilance.